Clinical Trials Logo

Clinical Trial Summary

This study will test the use of a new handheld device (called the N-Tidal C), that measures a person's tidal breath carbon dioxide, in diagnosing the cause of someone's breathlessness. It will also evaluate whether this device can detect when a person's breathing problem is getting worse.

Clinical Trial Description

When a person breathes out, they exhale carbon dioxide (CO2). The CO2 levels in breath change as they breathe out and this makes a specific pattern, or "waveform". This waveform can tell a clinician a lot about the underlying health of a person. There are disease specific CO2 waveforms for common breathing conditions such as Asthma and Chronic Obstructive Pulmonary Disease (COPD). However up until this point there has been no accurate and non-invasive method of measuring the tidal breath CO2 waveform.

This study will test the N-Tidal C, a new handheld device that accurately measures this waveform, and whether it can differentiate different causes of breathlessness; namely asthma, heart failure, pneumonia, breathing pattern disorders and motor neurone disease. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03356288
Study type Observational
Source Cambridge Respiratory Innovations Limited
Status Completed
Start date August 9, 2017
Completion date July 4, 2018

See also
  Status Clinical Trial Phase
Completed NCT03086460 - A Dose Ranging Study of CHF 1531 in Asthmatic Subjects Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Recruiting NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Active, not recruiting NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Completed NCT01318980 - A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A Phase 1
Recruiting NCT02782065 - Validation of the Hospital Asthma Severity Score (HASS)
Completed NCT02449473 - Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids Phase 2
Completed NCT02501629 - An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils Phase 3
Withdrawn NCT02546869 - A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting Phase 3
Completed NCT01691859 - MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects Phase 3
Completed NCT01687283 - Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma Phase 3
Completed NCT00446056 - Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379) Phase 4
Recruiting NCT03691961 - Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair) N/A
Completed NCT00972673 - A Study of GW685698X in Healthy Japanese Male Subjects Phase 1
Withdrawn NCT02794519 - A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma Phase 2
Recruiting NCT03528577 - A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited) Phase 3